Compare Heron Therapeutics Inc (HRTX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Royal Bank of Canada — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Royal Bank of Canada trades at $190.46 (market cap $262.99B). The key difference: Royal Bank of Canada is far larger — about 3866.9× Heron Therapeutics Inc's market cap, and Royal Bank of Canada pays a 2.66% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Royal Bank of Canada for 47 Days on average.
| HRTX | RY | |
|---|---|---|
Market Cap | $68.01M | $262.99B |
Volume | 1,891,941 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $1.49 | $217.87 |
52-Week Low | $0.27 | $143.64 |
Typical Hold Time | 35 Days | 47 Days |
Enterprise Value | $174.75M | $730.11B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Royal Bank of Canada (RY) trades at $190.31, down 0.48% with a bearish technical signal despite strong fundamentals. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with a 32.01% net margin, while analyst consensus shows 43% buy ratings amid mixed sentiment.
RY presents a valuation disconnect with solid profitability (17.2% ROE) against bearish technicals. Investment opportunity lies in consistent earnings growth and dividend yield, though risks include stretched valuations and negative cash flow trends. The stock faces headwinds from technical indicators but maintains fundamental strength for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
